NEW YORK, August 28, 2017 /PRNewswire/ --
If you want a Stock Review on ABT, BSX, EW, or MDT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. For today, DailyStockTracker.com dedicates investors' attention to Abbott Laboratories (NYSE: ABT), Boston Scientific Corp. (NYSE: BSX), Edwards Lifesciences Corp. (NYSE: EW), and Medtronic PLC (NYSE: MDT). These companies are part of the Medical Equipment market, which comprises surgical and medical instruments, surgical appliances and supplies, ophthalmic goods, dental laboratories, and in vitro reagents. Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
North Chicago, Illinois headquartered Abbott Laboratories' stock finished last Friday's session 0.06% lower at $49.35. A total volume of 4.85 million shares was traded. The Company's shares have advanced 10.38% over the previous three months and 28.48% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.57% and 11.64%, respectively. Additionally, shares of Abbott Labs, which manufactures and sells health care products worldwide, have a Relative Strength Index (RSI) of 51.67.
On August 15th, 2017, Abbott Labs and North West London Pathology, which is hosted by Imperial College Healthcare NHS Trust, announced that they signed a $252- million managed equipment services contract for the supply of all analytical equipment and consumables, including the former's Alinity™ ci and Alinity h series diagnostics instruments, as well as the duo's professional services and informatics solutions, known as AlinIQ.
On August 17th, 2017, research firm Citigroup initiated a 'Neutral' rating on the Company's stock, with a target price of $53 per share. Visit us today and access your complete report on ABT for free at:
On Friday, shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. ended the session 0.04% higher at $26.72. The stock recorded a trading volume of 3.67 million shares. The Company's shares have gained 23.53% on an YTD basis. The stock is trading 6.98% above its 200-day moving average. Moreover, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 44.42.
On August 21st, 2017, Boston Scientific announced that it is scheduled to participate in the Wells Fargo Healthcare Conference on September 07th, 2017, in Boston. Susie Lisa, Vice President, Investor Relations, will participate in a 30-minute, question-and-answer session with the host analyst, beginning at approximately 3:25 p.m. EDT that day. A live webcast of the session will be available under the Investor Relations section of the Company's website. The complimentary research report on BSX can be accessed at:
Irvine, California headquartered Edwards Lifesciences Corp.'s shares declined 0.88%, closing the session at $111.76. A total volume of 1.21 million shares was traded, which was above their three months average volume of 1.18 million shares. The stock has gained 19.27% on an YTD basis. The stock is trading 9.47% above their 200-day moving average. Additionally, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have an RSI of 35.44. Register for free on DailyStockTracker.com and download the research report on EW at:
Last Friday at the close, shares in Dublin, Ireland headquartered Medtronic PLC recorded a trading volume of 4.23 million shares. The stock ended the session 0.23% lower at $79.06. The Company's shares have advanced 10.99% since the start of this year. The stock is trading below its 200-day moving average by 2.17%. Furthermore, shares of Medtronic, which manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide, have an RSI of 20.92.
On August 21st, 2017, Medtronic announced that it has received CE (Conformité Européene) Mark for the Attain Stability[TM] Quad MRI SureScan[TM] left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators and -pacemakers, the Attain Stability Quad lead features novel, active-fixation technology that is designed for precise lead placement and stability. In the US, the Attain Stability Quad lead is under evaluation in a clinical trial and is not approved for sale. Get free access to your research report on MDT at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]racker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.